Pain Control
CAN-NCIC-PR6 Phase
III Randomized Study of Mitoxantrone and Prednisone With or Without Clodronate
in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain.
Chairperson: D. Scott Ernst. Telephone: 403-670-1761. Lead organization:
NCIC-Clinical Trials Group. Age range: any age.
RPCI-DS-95-35, NCI-G97-1352
Phase III Study of Epidural Hydromorphone
versus Intravenous Hydromorphone in Postoperative Radical Prostatectomy Patients.
Chairperson: Robert P. Sands,Jr. Telephone: 716-845-8630. Lead
organization: Roswell Park Cancer Institute. Age range: 18-70.
DIATIDE-117-22
Phase II Randomized Study of Tin Sn 117m DTPA versus Placebo in Patients With
Painful Osteolytic Bone Metastases.
Chairperson: Nancy J. Mulrow. Telephone: 603-437-8970. Lead organization:
Diatide, Inc. Age range: 18 and over.
DIATIDE-117-30, UCMC-97012201
Phase II Study of Sn-117m DTPA versus Strontium-89 in Patients With Painful
Bone Metastases Secondary to Prostate Cancer.
Chairperson: Nancy J. Mulrow. Telephone: 603-437-8970. Lead organization:
Diatide, Inc. Age range: 18 and over.
E-1Z95
Phase II Study of Flecainide for the Treatment of Chronic Neuropathic Pain.
Chairperson: Charles F. Von Gunten. Telephone: 312-908-9412. Lead
organization: Eastern Cooperative Oncology Group. Age range: over 18.
RPCI-DS-92-13, NCI-V97-1251
Randomized Study of the Peripheral Effects
of Opioid Analgesia in Patients With Breast Cancer Undergoing Axillary Node
Dissection.
Chairperson: Anthony T. Yarussi. Telephone: 716-845-8630. Lead
organization: Roswell Park Cancer Institute.
Age range: no age specified.
E-3Z93, NCI-P95-0068
Randomized Pilot Study to Evaluate Educational Intervention and Behavioral Skills
Training for Pain Control in Patients With Recurrent or Metastatic Breast or
Prostate Cancer.
Chairperson: Charles Cleeland. Telephone: 713-745-3470. Lead organization:
Eastern Cooperative Oncology Group. Age range: 18 and over.
E-4Z93, NCI-P93-0051
Oral Analgesia Regimen for Improved Pain Control in Cancer Patients.
Chairperson: Charles Cleeland. Telephone: 713-745-3470. Lead organization:
Eastern Cooperative Oncology Group. Age range: 18 and over.
Symptom Management/ Quality of Life
NCCTG-969257, NCI-P98-013
Phase III Randomized Study of Oral Capsaicin
Lozenges for Radiation Induced Mucositis.
Chairperson: Michael J. O’Connell. Telephone: 507-266-4997. Lead
organization: North Central Cancer Treatment Group. Age range: 18 and over.
CAN-NCIC-HN2
Phase III Study of Bacitracin, Clotrimazole, and Gentamicin (BCOG) Lozenges
versus Placebo Lozenges in Patients Undergoing Radiotherapy for Oral, Pharyngeal,
or Laryngeal Cancer.
Chairperson: Samy El-Sayed. Telephone: 204-787-2153. Lead organization:
NCIC-Clinical Trials Group. Age range: 16 and over.
RTOG-9709, NCI-P97-0121
Phase III Study of the Prophylactic Use
of Oral Pilocarpine to Reduce Hyposalivation and Mucositis Associated With Curative
Radiation Therapy in Patients With Head and Neck Cancer.
Chairperson: Francis LeVeque. Telephone: 313-745-9300. Lead organization:
Radiation Therapy Oncology Group. Age range: 18 and over.
RTOG-9801
Phase III Randomized Study of Amifostine Mucosal Protection in Patients With
Favorable Performance Inoperable Stage II, IIIA, or IIIB Non-Small Cell Lung
Cancer Receiving Sequential Induction and Concurrent Hyperfractioned Radiotherapy
With Paclitaxel and Carboplatin.
Chairperson: Benjamin Movsas. Telephone: 215-728-5304. Lead organization:
Radiation Therapy Oncology Group. Age range: 18 and over.
RTOG-9714, NCI-P97-0124,
NCCTG-R9714 Phase III Randomized Study
of Palliative Radiation Therapy for Bone Metastases From Breast or Prostate
Cancer.
Chairperson: William F. Hartsell. Telephone: 708-723-8030. Lead
or-ganization: Radiation Therapy Oncology Group. Age range: 18 and over.
CCCWFU-97194, NCI-P95-0064
Phase III Randomized, Double-blind Study of Warfarin vs Placebo for Chemoprevention
of Thrombosis in Central Venous Access Catheters in Cancer Patients.
Chairperson: Willard Abe Andes. Telephone: 910-716-9046. Lead
organization: Comprehensive Cancer Center of Wake Forest University Baptist
Medical Center. Age range: over 18.
SWS-SAKK-90/95, EU-97035
Phase III Randomized Study Comparing Granisetron
versus Metoclopramide in Combination With Dexamethasone in the Prophylaxis of
Chemotherapy-Induced Delayed Emesis.
Chairperson: Matti Aapro. Telephone: 41-22-366-9134 (Milano, Italy).
Lead organization: Swiss Institute for Applied Cancer Research. Age range: 18
and over.
CLB-9170, NCI-P93-0046
Phase III Randomized Study Comparing Continued Hospital Care vs Early Discharge
Therapy of Low-Risk Patients With Fever and Neutropenia.
Chairperson: James A. Talcott. Telephone: 617-724-5451. Lead organization:
Cancer and Leukemia Group B. Age range: 18 and over.
E-1Z93, NCI-P94-0059
Phase III Randomized Study of Sucralfate Suspension vs Topical Vitamin E for
the Treatment of Chemotherapy-Induced Mucositis.
Chairperson: Lisa A. Stucky-Marshall. Telephone: 312-908-6443.
Lead organization: Eastern Cooperative Oncology Group. Age range: 18 and over.
SCCC-92110, NCI-V93-0288
Phase II/III Pilot Study of Fluconazole
as Prophylaxis for Mucositis/ Thrush in Patients Undergoing Radiotherapy for
Head and Neck Cancer.
Chairperson: Arnold M. Markoe. Telephone: 305-243-4319. Lead organization:
Sylvester Cancer Center. Age range: over 21.
NCI-92-C-0134B, NCI-T92-0022N
Study of CPDG2 and Thymidine for the Management of Patients With MTX Toxicity
Secondary to Renal Dysfunction.
Chairman: Peter C. Adamson. Telephone: 301-496-7387. Lead organization:
Division of Clinical Sciences. Age range: any age.
RTOG-9604, NCI-P97-0122
Study to Validate the SOMA (Subjective, Objective, Management) Scale for Late
Effects of Normal Tissue after Radiation Therapy for Head and Neck Cancer.
Chairperson: Philip Rubin. Telephone: 716-275-2229. Lead organization:
Radiation Therapy Oncology Group. Age range: not specified.
URCC-U1996, NCI-P97-0088
Phase III Prevalence Study of Paroxetine
Hydrochloride for Fatigue in Cancer Patients Receiving Chemotherapy.
Chairperson: Jane T. Hickok. Telephone: 716-275-5513. Lead organization:
University of Rochester Cancer Center. Age range: 18 and over.
E-2Z96, NCI-P98-0130
Phase III Randomized Study of Methylphenidate
for Alleviation of Fatigue and Lethargy in Patients With Malignant Melanoma
Receiving Interferon Alfa.
Chairman: Robert L. Comis. Telephone: 215-893-6440. Lead organization:
Eastern Cooperative Oncology Group. Age range: 18 and over.
RPCI-DS-97-10, NCI-G98-1394,
ORTHO-PR-96-27-004 Phase III Randomized
Study of Epoetin Alfa versus Placebo in Anemic Patients Receiving Chemotherapy
for Stage IV Metastatic Breast Cancer.
Chairperson: Ellis G. Levine. Telephone: 716-845-8547. Lead organization:
Roswell Park Cancer Institute. Age range: 18-80.
NCCTG-959255, NCI-P96-0075
Phase III Randomized, Double-blind Study
of Megestrol vs Dronabinol vs Both in Patients With Cancer-Related Anorexia
and Cachexia.
Chairperson: Charles L. Loprinzi. Telephone: 507-284-8964. Lead
organization: North Central Cancer Treatment Group. Age range: 18 and over.
CAN-OTT-9605, NCI-V96-1084
Randomized Study of the Effect of Exercise
During Adjuvant Therapy on Quality of Life in Women With Stage I/II Breast Cancer.
Chairman: Roanne Segal. Telephone: 613-247-6803. Lead organization:
Ottawa Regional Cancer Centre - Civic Campus. Age range: 30 and over.
CAN-NCIC-SC16
Phase III Randomized Study of Oral Pilocarpine
for Patients With Opioid-Induced Dry Mouth.
Chairman: David Warr. Telephone: 416-946-2260. Lead organization:
NCIC-Clinical Trials Group. Age range: 16 and over.
EORTC-15961/40973
International Field Study of the Reliability
and Validity of the Quality-of-Life Questionnaire EORTC QLQ-C30 and the Disease-Specific
Module EORTC QLQ-OES-24 in Patients With Esophageal Cancer.
Chairman: Jane Blazeby. Telephone: +117 923 00 00 (England). Lead
organization: EORTC Quality of Life Study Group. Age range: any age.
CLB-9870
Companion Study to Evaluate Quality of
Life and Cost of Treatment in Patients With Esophageal Cancer Enrolled on CALGB
C9781.
Chairman: David G. Pfister. Telephone: 212-639-7477. Lead organization:
Cancer and Leukemia Group B. Age range: 18 and over.
GOCS-08-BR-95-III,
NCI-F95-0036 Phase III Randomized Study
of Neoadjuvant Fluorouracil/Doxorubicin/Cyclophosphamide (FAC) vs Cyclophosphamide/Methotrexate/Fluorouracil
(CMF) for Stage III Breast Cancer, With Quality of Life Assessed in Patients
Converted to Conservative Surgery vs Those Who Are Not.
Chairman: Bernardo A. Leone. Telephone: 54-99-485247 (Argentina).
Lead organization: Grupo Oncologico Cooperativo del Sur. Age range: pre/postmenopausal.
NCCTG-979253, NCI-P98-0133
Phase III Randomized Study of Epoetin Alfa
in Anemic Patients With Advanced Cancer Undergoing Chemotherapy.
Chairman: Michael J. O’Connell. Telephone: 507-266-4997. Lead
organization: North Central Cancer Treatment Group. Age range: 18 and over.
CAN-NCIC-SC14
Phase III Randomized Study of Theophylline
for the Treatment of Dyspnea in Cancer Patients.
Chairman: Deborah J. Dudgeon. Telephone: 613-545-6000, ext 7694.
Lead organization: NCIC-Clinical Trials Group. Age range: 16 and over.
SWOG-9208, CLB-9497
Companion Protocol to Evaluate Quality
of Life and Health Status in Patients With Stage I/IIA Hodgkin’s Disease Simultaneously
Enrolled on SWOG-9133 or CLB-9391.
Chairman: Patricia A. Ganz. Telephone: 310-206-1404. Lead organization:
Southwest Oncology Group. Age range: 18 and over.
MSKCC-97125, NCI-G98-1436,
ORTHO-MSKCC-97125, ORTHO-PR-96-27-031 Phase
III Randomized Study of the Effects of Epoetin Alfa on Hemoglobin, Symptoms
Distress, and Quality of Life During Chemotherapy in Lymphoma Patients With
Mild or Moderate Anemia.
Chairman: David J. Straus. Telephone: 212-639-8365. Lead organization:
Memorial Sloan-Kettering Cancer Center. Age range: 18 and over.
Legend for Abbreviations:
CAN-NCIC = National Cancer Institute of Canada
CCCWFU = Comprehensive Cancer Center of Wake Forest
University
CLB = Cancer & Leukemia Group B
CTI = Cell Therapeutics, Inc.
DIATIDE = Diatide, Inc.
E = Eastern Cooperative Oncology Group
EORTC = European Organization for Research on Treatment
of Cancer
EU = European Voluntary Protocol
GOCS = Grupo Oncologico Cooperativo del Sur
MSKCC = Memorial Sloan-Kettering Cancer Center
NCCTG = North Central Cancer Treatment Group
NCI = National Cancer Institute
ORTHO = Ortho Biotech, Inc.
RPCI = Roswell Park Cancer Institute
RTOG = Radiation Therapy Oncology Group
SCCC = Sylvester Comprehensive Cancer Center
SWOG = Southwest Oncology Group
SWS-SAKK = Swiss Group for Clinical Cancer Research
UCMC = University of Cincinnati
URCC = University of Rochester Cancer Center